Food and Staples Retailing Drug Retail

  • The pharmaceutical company reported its cancer drug failed to reach its goals for treating advanced non-small cell lung cancer.

  • *2nd- qtr adj. profit $1.32/ shr vs. est. CVS boosted its specialty pharmacy business, which provides drugs to people with expensive chronic conditions such as rheumatoid arthritis, with its $10.1 billion acquisition of Omnicare Inc in August 2015. The Woonsocket, Rhode Island- based company raised full-year adjusted earnings to $5.81- $5.89 per share, from $5.73-...

  • The Woonsocket, Rhode Island- based company raised full-year adjusted earnings to $5.81- $5.89 per share, from $5.73- $5.88 it had expected earlier. CVS boosted its specialty pharmacy business, which provides drugs to people with expensive chronic conditions such as rheumatoid arthritis, with its $10.1 billion acquisition of Omnicare Inc in August 2015.

  • Aug 2- CVS Health Corp, the No. 2 U.S. drugstore chain by store count, reported a 17.6 percent rise in quarterly revenue, helped by strength in its pharmacy business. The company's net revenue rose to $43.73 billion in the second quarter ended June 30, from $37.17 billion, a year earlier. Net income attributable to CVS Health fell to $924 million, or 86 cents per share, from...

  • *Q3 US retail sales up 0.1 pct vs. estimates of 0.7 pct. Co has been investing to revive U.S. retail business. July 6- Walgreens Boots Alliance Inc, the No.1 U.S. drugstore operator by store count, reported a lower-than-expected increase in quarterly sales, hurt by weak demand for over-the-counter drugs and other products.

  • *Q3 US retail sales up 0.1 pct vs. estimates of 0.7 pct. July 6- Walgreens Boots Alliance Inc, the No.1 U.S. drugstore operator by store count, reported a lower-than-expected increase in quarterly sales, hurt by weak demand for over-the-counter drugs and other products. The company also said on Wednesday it was bracing for a long period of volatility following...

  • *Q3 adjusted EPS $1.18 vs. estimates $1.14. July 6- Drugstore operator Walgreens Boots Alliance Inc reported a better-than-expected profit for the third quarter, helped by cost cuts and higher sales of Medicare Part D drugs in the United States. Walgreens did not say how, if at all, Britain's vote to leave the European Union would affect its business.

  • Teva Pharma Part 1

    Teva Pharmaceutical Industries' Yitzhak Peterburg says business is running as usual as it is still too early to determine Brexit's impact.

  • Merck's 'check point' therapy for cancer

    CNBC's Meg Tirrell talks with Merck's Roger Perlmutter about advances the drugmaker has made in treating cancer, including immunotherapy drug KEYTRUDA. Perlmutter also addresses concerns over the high price of drugs.

  • The case for more antibiotics

    A drug resistant bacteria is putting health officials on high alert, in which some are looking at the need for new antibiotics. Ezekiel Emanuel, Center for American Progress, discusses the dangers of over-prescription, and urges creation of new antibiotics.

  • Superbug found in US for first time

    Health officials report the first case of a patient with an infection resistant to all known antibiotics.

  • Capsule delivery service

    Capsule says its home-delivery prescription service will be faster and simpler for many consumers.

  • Tylenol could do more than relieve pain

    Researchers claim acetaminophen, the active ingredient in the medicine can decrease empathy.

  • Majority of Americans want to ban TV drug ads

    More than half of respondents say they would support removing prescription drug advertisements from TV.

  • Managing drug costs

    Best ways to reduce your prescription drug expenses – from using online retailers to getting 90-day supply.

  • Clinical trial for preventing migraines

    CNBC's Meg Tirrell reports on data from clinical trials by Alder and its migraine drug ALD403.

  • Positive study for marijuana-based drug to treat seizures

    GW Pharmaceuticals CEO Justin Gover, discusses the potential for Epidiolex for the treatment of Dravet syndrome.

  • Ex-drug CEO Shkreli tweets response House committee

    The House Oversight Committee wants Turing Pharmaceuticals founder Martin Shkreli to testify on the issue of raising drug prices, reports CNBC's Eamon Javers.

  • Rocky road for Chimerix

    CNBC's Meg Tirrell reports on the ups and downs for Chimerix's experimental drug brincidofovir.

  • Blackmores opens first Australian retail store

    CEO and MD Christina Holgate tells CNBC why the Supplement brand Blackmores decided to open its first retail store.